Authors
Latest:
Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis PatientsDavid Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
Latest:
Updates and Controversies in Necrotizing Soft Tissue InfectionsChanges in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.
Latest:
Education and Advocacy in DC: The PLF C Diff Summit and Lobby DayThe Peggy Lillis Foundation's (PLF) CEO and Cofounder Christian John Lillis talks about these important events happening in the capital at the end of this month.
Latest:
Computational Model Maps Over 67,000 Malaria Epitopes to Improve Vaccine TargetingAlexander Laurenson presents T-cell-focused tool at the 2025 Vaccinology Conference using data from 18 countries and 748 HLA alleles to address immune diversity in Africa.
Latest:
Targeting C difficile with Oxygen-Based TherapyLarry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.
Latest:
Antibiotic Stewardship Programs Help Curb Superbug Threat by Leveraging DataThe OASIS platform will help outpatient facilities use prescribing data to improve patient care.
Latest:
A Personnel Problem: We Need More Antimicrobial Researchers, Infectious Disease CliniciansA decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.
Latest:
A Clinician’s Perspective on Rebyota for Recurrent C Diff TreatmentTimothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.
Latest:
Clinicians Discuss the State of Vaccines TodayA panel discusses how vaccine policy under new federal government policies, why misinformation has flourished and what individual providers can do to win back patient trust.
Latest:
China Reports Over 7,000 Chikungunya Cases in Guangdong Province Amid Aggressive Containment EffortsChina's largest recorded chikungunya outbreak prompts strict mosquito control and mandatory hospitalization in Foshan.
Latest:
A Win for Coverage, but Can People Still Access HIV Prevention?Carl Schmid on the US Supreme Court ruling, proposed Centers for Disease Control and Prevention cuts, stigma, and why equitable PrEP access, including new long-acting options, depends on more than insurance.
Latest:
Sweeping Public Health Changes Create US and Global TurmoilWith the Trump administration’s plans to cease funding for Gavi, the Vaccine Alliance, as well as to reduce the US Department of Health and Human Services personnel, public health, both internationally and domestically, is going to be widely affected.
Latest:
ALLIANCE Study: B/F/TAF Achieves Sustained HIV and HBV SuppressionAnchalee Avihingsanon, MD, PhD presents results showing 95.4% HIV RNA suppression and 86.6% HBV DNA suppression after 48 weeks of B/F/TAF in HIV-HBV co-infected patients.
Latest:
How a Prodrug Approach May Aid In Antimalarial DevelopmentSesh Sundararaman, MD, PhD, discusses his findings and how this approach can be triggered to minimize undesirable treatment features and open the door to newer treatment possibilities.
Latest:
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility TestingThe Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Latest:
The Lingering Threat: Managing Severe COVID-19 in the Postpandemic EraAlthough COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.
Latest:
Advancing STOP2030 Treatment in Global HealthAlejandro Krolewiecki, MD discusses the path to regulatory approval, collaboration with global health organizations, and the role of partnerships in scaling up the new treatment for neglected tropical diseases.
Latest:
The Impact of Widespread RSV Vaccination and Quantifying ResultsIn the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.
Latest:
Fluoroquinolone Safe for Treating Severe Refractory M Pneumoniae PneumoniaInvestigators asked the children’s parents about the history of musculoskeletal-related disease, observed the children’s gait, and performed physical examinations.
Latest:
Navigating the Challenges of CMS AUR Reporting Mandates: Penalties, Progress, and PitfallsThe long-term benefits of antimicrobial use and resistance (AUR) reporting is about improving patient care and combating resistance.
Latest:
Examining the HIV Treatment PipelineA review of selected investigational long-active treatment options for HIV.
Latest:
Does Slow Viral Clearance and Viral Rebound During Infection Contribute to Long COVID?Annie Antar, MD, PhD, offers insights around her research on her findings on this subject.
Latest:
Vegetable Oil-Based Diet Supports Liver Health in Chronic Hepatitis B PatientsUnsaturated fats in vegetable oils help reduce inflammation and modulate organ metabolism, leading to decreased ALT, AST, and TBIL levels.
